$ARLZ-NASDAQ-Pharma-$1.51-Aralez Announces Departure of Chief Financial Officer
Today 5:00 PM ET (PR NewsWire)Print
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that Scott J. Charles, Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately. Michael Kaseta will assume the position of Interim Chief Financial Officer ("CFO") along with his current duties as Corporate Controller. Mr. Kaseta has served as Corporate Controller since 2016 and brings a breadth of experience in all aspects of the Company's financial operations. Prior to joining Aralez, Mr. Kaseta served as CFO of Sanofi North America, Global Services.
"The Board and I want to wish Scott the best in his future endeavors," said Adrian Adams, Chief Executive Officer of Aralez. "We have full confidence in Mike's ability to lead our finance operations, and we expect a seamless transition. As outlined in our recent third quarter press release, we are now positioning the Company for the next phase of growth as illustrated in our updated 2017 financial guidance and preliminary 2018 outlook. We are confident that we are on the pathway to achieve sustained profitability and growth as we execute on our goals to deliver shareholder value."
About Aralez Pharmaceuticals Inc.Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is in Princeton, New Jersey and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.
Aralez Pharmaceuticals US Inc. Contact: Nichol L. OchsnerExecutive Director, Investor Relations & Corporate Communications732-754-2545nochsner@aralez.com
